Treatment with drug-resistant cell lines (CEM/ADR5000, MDA-MB-231/BCRP, HCT116(p53−/−), and U87MG/ΔEGFR cells) with thiazole-containing chalcone derivatives (35, IC50: 2.72–41.04 μM) was found to induce significant hypersensitivity effects, suggesting that these compounds are suitable molecules to combat the drug resistance of cancer cells [76]. This evidence concerns the gene TP53 and cancer.